Thalassemia

Study confirms safety and efficacy of deferiprone

Published in Drug Week, October 17th, 2003

A new study reports impressive results from a large, long-term prospective study examining the safety and efficacy of deferiprone, an orally active medicine for the treatment of iron overload in thalassemia, a rare genetic blood disorder.

Deferiprone (Ferriprox) is the first oral iron treatment to be approved by a regulatory agency and serves as a hope for those patients who cannot tolerate the injectable drug that had been the only treatment available for the past 30 years.

The study by lead investigator Dr. Alan Cohen of the Children's Hospital of Philadelphia is the largest study to have reported continuous use of deferiprone over a 4-year period,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2003-10-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry